MX2020003732A - Derivado de anillo fusionado como inhibidor del receptor a2a. - Google Patents

Derivado de anillo fusionado como inhibidor del receptor a2a.

Info

Publication number
MX2020003732A
MX2020003732A MX2020003732A MX2020003732A MX2020003732A MX 2020003732 A MX2020003732 A MX 2020003732A MX 2020003732 A MX2020003732 A MX 2020003732A MX 2020003732 A MX2020003732 A MX 2020003732A MX 2020003732 A MX2020003732 A MX 2020003732A
Authority
MX
Mexico
Prior art keywords
fusioned
receptor inhibitor
ring derivative
receptor
compound
Prior art date
Application number
MX2020003732A
Other languages
English (en)
Other versions
MX383975B (es
Inventor
Shuhui Chen
CHEN Kevin X
Kai Zhou
Boyu Hu
Minliang Xiao
Original Assignee
Cstone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Suzhou Co Ltd filed Critical Cstone Pharmaceuticals Suzhou Co Ltd
Publication of MX2020003732A publication Critical patent/MX2020003732A/es
Publication of MX383975B publication Critical patent/MX383975B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable de este, y una aplicación del compuesto o sal en la preparación de fármacos para tratar enfermedades relacionadas con un receptor A2A.
MX2020003732A 2017-09-28 2018-09-27 Derivado de anillo fusionado como inhibidor del receptor a2a MX383975B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710900542 2017-09-28
CN201810239824 2018-03-21
PCT/CN2018/107899 WO2019062803A1 (zh) 2017-09-28 2018-09-27 作为a2a受体抑制剂的并环类衍生物

Publications (2)

Publication Number Publication Date
MX2020003732A true MX2020003732A (es) 2021-06-29
MX383975B MX383975B (es) 2025-03-14

Family

ID=65900821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003732A MX383975B (es) 2017-09-28 2018-09-27 Derivado de anillo fusionado como inhibidor del receptor a2a

Country Status (15)

Country Link
US (1) US11312715B2 (es)
EP (1) EP3686199B9 (es)
JP (1) JP6836693B2 (es)
KR (1) KR102254660B1 (es)
CN (1) CN111542520B (es)
AU (1) AU2018341781B2 (es)
CA (1) CA3077267C (es)
ES (1) ES2927086T3 (es)
IL (1) IL273606B (es)
MX (1) MX383975B (es)
RU (1) RU2748993C1 (es)
SA (1) SA520411635B1 (es)
SG (1) SG11202002886PA (es)
TW (1) TWI788424B (es)
WO (1) WO2019062803A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655509B (zh) * 2018-06-29 2023-01-24 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN111094254B (zh) * 2018-07-12 2022-07-26 江苏恒瑞医药股份有限公司 杂芳基类衍生物、其制备方法及其在医药上的应用
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
JP7536036B2 (ja) * 2019-03-28 2024-08-19 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド Ａ２ａ受容体アンタゴニストの塩形態、結晶形態及びその製造方法
CN118955502A (zh) * 2020-07-23 2024-11-15 上海赛岚生物科技有限公司 一类具有激酶抑制活性的化合物
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150671T3 (es) 1995-04-21 2000-12-01 Neurosearch As Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
WO1998042711A1 (en) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
RU2251419C2 (ru) 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
HUP0700086A2 (en) * 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
DK1737831T3 (da) * 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
SI2408775T1 (sl) 2009-03-20 2015-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila
DE102012019369A1 (de) * 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RU2534804C1 (ru) 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
JP6275410B2 (ja) 2013-08-06 2018-02-07 大和ハウス工業株式会社 固定具
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
CN110678466B (zh) * 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类

Also Published As

Publication number Publication date
US11312715B2 (en) 2022-04-26
RU2748993C1 (ru) 2021-06-02
CA3077267A1 (en) 2019-04-04
EP3686199A4 (en) 2021-04-07
MX383975B (es) 2025-03-14
AU2018341781B2 (en) 2023-03-30
AU2018341781A1 (en) 2020-04-30
SA520411635B1 (ar) 2022-05-24
ES2927086T3 (es) 2022-11-02
EP3686199B9 (en) 2022-12-07
EP3686199A1 (en) 2020-07-29
CA3077267C (en) 2021-02-16
US20200239465A1 (en) 2020-07-30
TW201920171A (zh) 2019-06-01
JP6836693B2 (ja) 2021-03-03
SG11202002886PA (en) 2020-04-29
BR112020006185A2 (pt) 2020-10-13
KR102254660B1 (ko) 2021-05-24
IL273606B (en) 2021-05-31
TWI788424B (zh) 2023-01-01
WO2019062803A1 (zh) 2019-04-04
JP2020535196A (ja) 2020-12-03
KR20200055126A (ko) 2020-05-20
CN111542520A (zh) 2020-08-14
AU2018341781A8 (en) 2020-05-07
CN111542520B (zh) 2022-04-15
IL273606A (en) 2020-05-31
EP3686199B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
DOP2019000201A (es) Compuestos inhibidores del vih
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CO2019004034A2 (es) Compuesto de piridina
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR103680A1 (es) Inhibidores selectivos de bace1
DOP2017000034A (es) Compuestos de imidazopiridazina
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
NI201800071A (es) Compuestos de isoindol
CR20160527A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
PY1446505A (es) Compuestos derivados de piridilo biciclicos fusionados a anilo como inhibidores de fgfr4